

# Financial Tear Sheet

## Corporate Profile

Altimmune is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer, with the potential for fundamental advantages over competing products.

## Corporate Profile


### ALT (COMMON STOCK)

**\$3.93**

Change (%) ▲ 0.13 (3.42%)

Volume 34,490

Data as of 06/22/17 4:00 p.m. ET  
 Data provided by Nasdaq. Minimum 15 minutes delay  
[Refresh quote](#)



## Recent Press Releases

June 19, 2017

[ALTIMMUNE TO PROVIDE CORPORATE UPDATE AT THE BIO INTERNATIONAL CONVENTION](#)

May 16, 2017

[ALTIMMUNE PROMOTES DR. SYBIL TASKER TO CHIEF MEDICAL OFFICER](#)

May 10, 2017

[ALTIMMUNE, INC. \(NASDAQ: ALT\) TO RING THE NASDAQ STOCK MARKET OPENING BELL](#)

## Upcoming Events



June 19, 2017 through June 20, 2017

[ALTIMMUNE, INC. AT THE BIO INTERNATIONAL CONVENTION](#)

## Sec Filings

Filing Date	Form	Description	Filing Group
06/09/17	8-K	Report of unscheduled material events or corporate event	Current Reports
06/08/17	4	Statement of changes in beneficial ownership of securities	3,4,5
06/06/17	4	Statement of changes in beneficial ownership of securities	3,4,5
05/16/17	8-K	Report of unscheduled material events or corporate event	Current Reports
05/15/17	8-K	Report of unscheduled material events or corporate event	Current Reports
05/15/17	SC 13G	A statement of beneficial ownership of common stock by certain persons	Other

05/15/17	<a href="#">SC 13D</a>	Filing by person(s) reporting owned shares of common stock in a public company >5%	Other
05/15/17	<a href="#">3</a>	Initial filing by director officer or owner of more than ten percent.	3,4,5
05/15/17	<a href="#">SC 13G</a>	A statement of beneficial ownership of common stock by certain persons	Other
05/10/17	<a href="#">8-K</a>	Report of unscheduled material events or corporate event	Current Reports

## Primary IR Contact

Matthew Duffy  
Phone: (212) 915-0685  
E-mail: [matthew@lifesciadvisors.com](mailto:matthew@lifesciadvisors.com)